



Press release

## Good Manufacturing Practices certificate issued by the ANSM

Dijon, 16 November 2021

**CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations, announces that it has obtained the GMP certificate issued by the ANSM.**

Patrick Alexandre, Crossject CEO, said: *“The Good Manufacturing Practices (GMP) certificate of compliance that has just been issued by the ANSM confirms that Crossject meets the quality standards set by drug manufacturing regulations. The certificate illustrates our demanding quality strategy. It is an essential element in supporting Crossject’s future development.”*

Crossject obtained pharmaceutical establishment status in 2019. As part of its role in the supervision of drug markets, the ANSM (National Agency for the Safety of Medicines and Health Products) carried out an initial inspection of the company’s premises. Following the inspection, the regulatory compliance of Crossject’s quality system has been confirmed by the issuance of a Good Manufacturing Practices (GMP) certificate.

As a reminder, pharmaceutical establishment status authorises Crossject to release clinical batches and perform quality controls on finished products for human use in its own laboratory.



## Contacts:

**Crossject**  
Patrick Alexandre  
[info@crossject.com](mailto:info@crossject.com)

**Investor relations**  
**CIC Market Solutions**  
Catherine Couanau +33 (0)1 53 48 81 97  
[catherine.couanau@cic.fr](mailto:catherine.couanau@cic.fr)

**Press relations**  
**Buzz & Compagnie**  
Mélanie Voisard +33 (0)3 80 43 54 89  
[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)  
Christelle Distinguin +33 (0)3 80 43 54 89  
[christelle.distinguin@buzzetcompagnie.com](mailto:christelle.distinguin@buzzetcompagnie.com)

## About CROSSJECT • [www.crossject.com](http://www.crossject.com)

Crossject (ISIN: FRO011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.